

Aesthetic Efficacy of a Novel Topical Combination Brightening Regimen to Treat Facial Hyperpigmentation

Lisa T. Goberdhan, MSHS¹, Katie Schneider, BS¹, Arielle Bautista, BS¹, Elizabeth T. Makino, BS CCRA MBA¹, Rahul C. Mehta, PhD¹

¹Allergan Aesthetics, an AbbVie Company, Irvine, CA, USA

OBJECTIVE

To assess the cosmetic changes of a combination regimen of a novel brightening serum, spot treatment and brightening pads in subjects with mild to severe facial hyperpigmentation.

CONCLUSIONS

Visible improvements in the appearance of hyperpigmentation, photodamage, tactile roughness, lines/wrinkles, radiance, and skin tone evenness with consistent use of the EC Regimen

EC Regimen provided significant improvements in a variety of visible hyperpigmentation concerns as early as Week 1 with continued significant improvements through week 12 versus baseline

EC Regimen was a well-tolerated, effective combination for improving multiple hyperpigmentation and photoaging parameters with high patient satisfaction.

INTRODUCTION

- Hyperpigmentation is a multifaceted condition that is often challenging to treat.
- Due to this complexity, a combination therapy providing a holistic approach of removal and prevention of pigmentation has shown greater efficacy than a monotherapy treatment.
- **A clinical usage study was conducted to assess the cosmetic changes of a combination take-home skincare topical regimen of a novel brightening platform (EC regimen: pads, serum, and spot cream) in subjects with mild to severe facial hyperpigmentation.**

METHODS

Study Design: 12 week, Open-label, Single-Center Study

Primary Efficacy Analysis



EC Brightening Pads and EC Serum twice-daily; EC Spot Cream once-daily in PM

Participants



- n=19; males and females aged 31-69, self-identified ethnicities: Asian, White, American Indian, and Hispanic
- Fitz I-IV with mild to severe overall facial hyperpigmentation (score of 3-9 on a modified Griffiths 10-point scale) on the face

Study Assessments

- Dark Spot Intensity and Dark Spot Contrast grades
- Modified Melasma Area and Severity Index (mMASI) scores
- Observations of Overall Hyperpigmentation, Overall Photodamage, Tactile Roughness, Skin Tone Evenness, Fine and Coarse Lines/Wrinkles, and Radiance
- Participant self-assessment questionnaires

RESULTS

EC Regimen significantly improved dark spot (a) intensity and (b) contrast as early as Week 1 with continued improvements through Week 12 relative to baseline




Visible improvements in hyperpigmentation of a 38-year-old, white female with Fitzpatrick Skin Type II at Baseline, Week 8, and Week 12 (VISIA-CR images)




Visible improvements in hyperpigmentation, photodamage, line/wrinkles, texture, and radiance of a 69-year-old, Asian female with Fitzpatrick Skin Type III at Baseline, Week 1, and Week 12 (VISIA-CR parallel-polarized images)



Modified MASI scores following consistent use of the EC Regimen were improved as early as week 2 with continued improvements through week 12 versus baseline



Tolerability scores remained mild for all tolerability parameters throughout the study EC Regimen was highly-rated by subjects



For additional information or to obtain a PDF of this poster

Scan QR code or use the following link to download an electronic version of this presentation and other Allergan Aesthetics and AbbVie 2023 Fall CDC scientific presentations: <https://abbvie1.outsystemsenterprise.com/GMAEventPublications/Assets.aspx?ConferenceId=667>

QR code expiration: Oct 19, 2024

To submit a medical question, please visit www.abbviemedinfo.com



Allergan Aesthetics, an AbbVie Company, and the authors thank the participants, study sites, and investigators who participated in this clinical trial.

Allergan Aesthetics, an AbbVie Company, funded this trial and participated in the trial design, research, analysis, data collection, interpretation of data, and the review and approval of the publication. All authors had access to relevant data and participated in the drafting, review, and approval of this publication. No honoraria or payments were made for authorship. No writing support was provided.

Financial arrangements of the authors with companies whose products may be related to the present report are listed as declared by the authors: Lisa T. Goberdhan, Katie Schneider, Arielle Bautista, Elizabeth T. Makino, and Rahul C. Mehta are full-time employees of AbbVie.

Allergan Aesthetics
an AbbVie company